Therapy of recurrent high grade gliomas with surgery, and autologous mitogen activated IL-2 stimulated killer (MAK) lymphocytes: I. Enhancement of MAK lytic activity and cytokine production by PHA and clinical use of PHA. (Q48333805)

From Wikidata

Jump to navigation Jump to search

scientific article published in February 1993

Language	Label	Description	Also known as
English	Therapy of recurrent high grade gliomas with surgery, and autologous mitogen activated IL-2 stimulated killer (MAK) lymphocytes: I. Enhancement of MAK lytic activity and cytokine production by PHA and clinical use of PHA.	scientific article published in February 1993

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/8509819

Therapy of recurrent high grade gliomas with surgery, and autologous mitogen activated IL-2 stimulated killer (MAK) lymphocytes: I. Enhancement of MAK lytic activity and cytokine production by PHA and clinical use of PHA. (English)

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/8509819

author name string

E W Jeffes

1

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/8509819

Y B Beamer

2

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/8509819

S Jacques

3

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/8509819

R S Silberman

4

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/8509819

B Vayuvegula

5

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/8509819

S Gupta

6

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/8509819

J S Coss

7

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/8509819

R S Yamamoto

8

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/8509819

G A Granger

9

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/8509819

publication date

1 February 1993

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/8509819

Journal of Neuro-Oncology

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/8509819

15

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/8509819

2

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/8509819

141-155

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/8509819

Grading of astrocytomas. A simple and reproducible method.

1 reference

https://pubmed.ncbi.nlm.nih.gov/8509819

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pulmonary embolism as a cause of death in the neurosurgical patient

1 reference

https://pubmed.ncbi.nlm.nih.gov/8509819

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rat mitogen-stimulated lymphokine-activated T killer cells: production and effects on C6 glioma cells in vitro and in vivo in the brain of Wistar rats

1 reference

https://pubmed.ncbi.nlm.nih.gov/8509819

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intratumoral LAK cell and interleukin-2 therapy of human gliomas.

1 reference

https://pubmed.ncbi.nlm.nih.gov/8509819

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Generation of stimulated, lymphokine activated T killer (T-LAK) cells from the peripheral blood of normal donors and adult patients with recurrent glioblastoma.

1 reference

https://pubmed.ncbi.nlm.nih.gov/8509819

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunotherapy for recurrent malignant glioma: an interim report on survival

1 reference

https://pubmed.ncbi.nlm.nih.gov/8509819

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interleukin-2-activated lymphocytes from brain tumor patients. A comparison of two preparations generated in vitro

1 reference

https://pubmed.ncbi.nlm.nih.gov/8509819

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo

1 reference

https://pubmed.ncbi.nlm.nih.gov/8509819

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Analysis of the murine lymphokine-activated killer (LAK) cell phenomenon: dissection of effectors and progenitors into NK- and T-like cells.

1 reference

https://pubmed.ncbi.nlm.nih.gov/8509819

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Survival in glioblastoma: historical perspective.

1 reference

https://pubmed.ncbi.nlm.nih.gov/8509819

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adoptive Immunotherapy of Established Pulmonary Metastases with LAK Cells and Recombinant Interleukin-2

1 reference

https://pubmed.ncbi.nlm.nih.gov/8509819

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Characterization of the lysis of fresh human solid tumors by autologous lymphocytes activated in vitro with phytohemagglutinin

1 reference

https://pubmed.ncbi.nlm.nih.gov/8509819

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In vivo and in vitro effect of adoptive immunotherapy of experimental murine brain tumors using lymphokine-activated killer cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/8509819

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In vitro cytolysis of primitive neuroectodermal tumors of the posterior fossa (medulloblastoma) by lymphokine-activated killer cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/8509819

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A simple nonisotopic in vitro bioassay for LT and TNF employing sodium fluoride-treated L-929 target cells that detects picogram quantities of LT and TNF and is as sensitive as TNF assays done with ELISA methodology

1 reference

https://pubmed.ncbi.nlm.nih.gov/8509819

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The LT system in experimental animals. II. Physical and immunologic characteristics of molecules with LT activity rapidly released by murine lymphoid cells activated on lectin-coated allogeneic monolayers in vitro

1 reference

https://pubmed.ncbi.nlm.nih.gov/8509819

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes

1 reference

https://pubmed.ncbi.nlm.nih.gov/8509819

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes

1 reference

https://pubmed.ncbi.nlm.nih.gov/8509819

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report

1 reference

https://pubmed.ncbi.nlm.nih.gov/8509819

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2

1 reference

https://pubmed.ncbi.nlm.nih.gov/8509819

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cancer immunotherapy: current status of treatment with interleukin 2 and lymphokine-activated killer cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/8509819

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Massive preoperative pulmonary embolism and suprasellar brain tumor: case report and review of the literature

1 reference

https://pubmed.ncbi.nlm.nih.gov/8509819

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phenotypic and functional analysis of lymphokine-activated killer (LAK) cell clones. Ability of CD3+, LAK cell clones to produce interferon-gamma and tumor necrosis factor upon stimulation with tumor targets

1 reference

https://pubmed.ncbi.nlm.nih.gov/8509819

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Reoperation for glioblastoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/8509819

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Glioblastoma multiforme and anaplastic astrocytoma. Pathologic criteria and prognostic implications

1 reference

https://pubmed.ncbi.nlm.nih.gov/8509819

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inhibition of human lymphocyte-mediated mitogen-induced cytotoxicity of murine L-929 cells by heterologous anti-human lymphotoxin antisera in vitro

1 reference

https://pubmed.ncbi.nlm.nih.gov/8509819

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intralesional infusion of lymphokine-activated killer (LAK) cells and recombinant interleukin-2 (rIL-2) for the treatment of patients with malignant brain tumor

1 reference

https://pubmed.ncbi.nlm.nih.gov/8509819

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interleukin-2 and autologous lymphokine-activated killer cells in the treatment of malignant glioma. Preliminary report

1 reference

https://pubmed.ncbi.nlm.nih.gov/8509819

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone

1 reference

https://pubmed.ncbi.nlm.nih.gov/8509819

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The human LT serum. X. The initial form released by T-enriched lymphocytes is 150,000 m.w., associated with small nonlytic components, and can dissociate into the smaller alpha, beta, and gamma m.w. classes

1 reference

https://pubmed.ncbi.nlm.nih.gov/8509819

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The LT system in experimental animals. I. Rapid release of high levels of lymphotoxin (LT) activity from murine lymphocytes during the interaction with lectin-treated allogeneic or xenogeneic target cells in vitro

1 reference

https://pubmed.ncbi.nlm.nih.gov/8509819

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin 2 (RIL 2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/8509819

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Local administration of autologous lymphokine-activated killer cells and recombinant interleukin 2 to patients with malignant brain tumors.

1 reference

https://pubmed.ncbi.nlm.nih.gov/8509819

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Salvage immunotherapy of malignant glioma

1 reference

https://pubmed.ncbi.nlm.nih.gov/8509819

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lymphocyte Effector Molecules and Cell-Mediated Immune Reactions

1 reference

https://pubmed.ncbi.nlm.nih.gov/8509819

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Thrombosis and intracranial tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/8509819

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/BF01053935

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/8509819

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/8509819

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q48333805&oldid=2209341757"